RT Journal Article
SR Electronic
T1 Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia — The PUSH-PATH3 Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.141037
DO 10.3899/jrheum.141037
A1 Hong Meng
A1 Gang Liu
A1 Jianlong Zhai
A1 Yuzhi Zhen
A1 Qingzhen Zhao
A1 Mingqi Zheng
A1 Guoping Ma
A1 Le Wang
A1 Li Tian
A1 Lishuang Ji
A1 Linan Duan
A1 Lizhuo Li
A1 Kunshen Liu
A1 Chao Liu
YR 2015
UL http://www.jrheum.org/content/early/2015/03/10/jrheum.141037.abstract
AB Objective To determine the safety and efficacy of prednisone in patients with symptomatic heart failure (HF) and hyperuricemia. Methods Prednisone therapy was administered for a short time to 191 symptomatic HF patients with hyperuricemia (serum uric acid > 7 mg/dl). Results Prednisone significantly reduced serum uric acid by 2.99 mg/dl (p < 0.01) and serum creatinine by 0.17 mg/dl (p < 0.01). These favorable effects were associated with a remarkable increase in urine output, improvement in renal function, and improvement in clinical status. Conclusion Prednisone can be used safely in symptomatic HF patients with hyperuricemia.